SANTA MONICA, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)PROSTATE CANCER FOUNDATION, founded in 1993, is a mid-sized nonprofit in the Philanthropy & Grantmaking sector that reported $56.7M in total revenue in fiscal year 2024.
THE PROSTATE CANCER FOUNDATION (PCF) FUNDS THE WORLD'S MOST PROMISING RESEARCH ON THE BIOLOGY AND TREATMENT OF PROSTATE CANCER, ACCELERATING THOSE DISCOVERIES INTO THERAPIES AND STRATEGIES DESIGNED TO IMPROVE THE QUALITY OF LIFE AND OVERALL SURVIVAL OF PATIENTS. PCF IS COMMITTED TO THE MISSION OF ENDING DEATH AND SUFFERING FROM THE DISEASE.
THE PCF RESEARCH ENTERPRISE IS A PEER-REVIEW RESEARCH FUNDING PROGRAM THAT PROVIDES FUNDING TO 2,250 SCIENTISTS CONDUCTING INNOVATIVE RESEARCH PROJECTS AT MORE THAN 245 LEADING CANCER CENTERS AND...
THE PCF RESEARCH ENTERPRISE IS A PEER-REVIEW RESEARCH FUNDING PROGRAM THAT PROVIDES FUNDING TO 2,250 SCIENTISTS CONDUCTING INNOVATIVE RESEARCH PROJECTS AT MORE THAN 245 LEADING CANCER CENTERS AND UNIVERSITIES. PRIORITY IS GIVEN TO HIGH-RISK, HIGH-RETURN PROJECTS WITH THE GREATEST POTENTIAL TO IMPROVE SURVIVAL AND THE OVERALL QUALITY OF LIFE FOR MEN WITH PROSTATE CANCER. THE CORNERSTONE OF THE PCF RESEARCH ENTERPRISE IN 2024 WAS OUR CHALLENGE AWARDS PROGRAM AND NEW TACTICAL AWARDS PROGRAM, WHICH SUPPORT CROSS-DISCIPLINARY TEAMS OF INVESTIGATORS CONDUCTING PIONEERING RESEARCH TO ADDRESS CRITICAL UNMET MEDICAL NEEDS FOR PROSTATE CANCER PATIENTS. IN 2024, PCF FUNDED 15 MULTI-YEAR TEAM RESEARCH PROJECTS THAT EACH OFFER HIGH POTENTIAL FOR IMPROVED DETECTION, ENHANCED QUALITY OF LIFE AND HIGHER SURVIVAL RATES.
FOR MORE THAN 3 MILLION AMERICAN MEN AND THEIR FAMILIES FIGHTING PROSTATE CANCER AND MILLIONS MORE GLOBALLY, PCF SERVES AS A PRIMARY SOURCE FOR NEW STANDARD-OF-CARE AND RESEARCH INFORMATION. PCF...
FOR MORE THAN 3 MILLION AMERICAN MEN AND THEIR FAMILIES FIGHTING PROSTATE CANCER AND MILLIONS MORE GLOBALLY, PCF SERVES AS A PRIMARY SOURCE FOR NEW STANDARD-OF-CARE AND RESEARCH INFORMATION. PCF EDUCATES THE PUBLIC ABOUT PROSTATE CANCER RISKS, SCREENING, PREVENTION, TREATMENT OPTIONS, AND SIDE EFFECTS. WE CONNECT PATIENTS, LOVED ONES, CARE PROVIDERS, AND SCIENTISTS TO CRITICAL UPDATES, THE LATEST DEVELOPMENTS, BEST PRACTICES, AND NEWS FROM THE TREATMENT PIPELINE. SINCE PCF'S INCEPTION, AND THROUGH ITS EFFORTS, PATIENTS AROUND THE WORLD ARE LIVING LONGER, SUFFERING FEWER COMPLICATIONS, AND ENJOYING BETTER QUALITY OF LIFE. PCF AIMS TO SPUR MEN AND WOMEN ALIKE TO TALK ABOUT THIS DISEASE, TO UNDERSTAND ITS URGENCY, AND TO HAVE INFORMATION-DRIVEN HOPE.
PCF CREATED THE YOUNG INVESTIGATOR AWARD PROGRAM WITH ONE GOAL: TO BUILD A GIFTED COHORT OF HUMAN CAPITAL SUPPORTING THE NEXT GENERATION OF PROSTATE CANCER RESEARCHERS. AWARDS ARE MADE TO...
PCF CREATED THE YOUNG INVESTIGATOR AWARD PROGRAM WITH ONE GOAL: TO BUILD A GIFTED COHORT OF HUMAN CAPITAL SUPPORTING THE NEXT GENERATION OF PROSTATE CANCER RESEARCHERS. AWARDS ARE MADE TO EARLY-CAREER SCIENTISTS WORKING IN A RESEARCH ENVIRONMENT CAPABLE OF SUPPORTING HIGH-IMPACT PROSTATE CANCER RESEARCH, DRAWN FROM A VARIETY OF MEDICAL RESEARCH DISCIPLINES. IN ITS 27TH YEAR, THE PCF PROGRAM HAS AWARDED NEARLY $93 MILLION TO ADVANCE THE CAREERS OF 435 PCF YOUNG INVESTIGATORS, ENSURING A CONTINUED STREAM OF HUMAN CAPITAL INTO OUR RESEARCH COMMUNITY. THE PCF YOUNG INVESTIGATOR PROGRAM PLAYS AN INTEGRAL ROLE IN CHAMPIONING, MENTORING, AND IDENTIFYING FUTURE MEDICAL RESEARCH PROGRAM LEADERS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $56,686,215 | $57,291,095 | 0.0% |
| Expenses | $58,177,919 | $55,134,763 | +0.1% |
| Net Income | $-1,491,704 | $2,156,332 | -1.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| CHARLES RYAN | CEO (DEPARTED 2/2024) | 60.00 |
Officer
|
$961,414 | $19,569 | $980,983 |
| GINA CARITHERS | PRESIDENT & CEO | 50.00 |
Officer
|
$640,810 | $13,800 | $654,610 |
| HOWARD SOULE | EVP, CHIEF SCIENCE OFFICER | 50.00 |
Officer
|
$581,029 | $56,136 | $637,165 |
| HELEN HSIEH | EVP, FINANCE, CAO | 50.00 |
Key Emp
|
$390,901 | $55,487 | $446,388 |
| JANET HABER | VP, EVENTS | 50.00 |
Highest
|
$263,482 | $22,400 | $285,882 |
| CHRISTOPHER CONWAY | VP, SPORTS | 50.00 |
Highest
|
$243,079 | $17,761 | $260,840 |
| GEORGE CHONG | CONTROLLER | 50.00 |
Highest
|
$228,630 | $31,565 | $260,195 |
| STUART HOLDEN MD | DIRECTOR/MEDICAL DIRECTOR | 30.00 |
Director
|
$225,000 | $0 | $225,000 |
| ANDREA MIYAHIRA | SENIOR DIRECTOR, SCIENCE | 50.00 |
Highest
|
$198,756 | $49,256 | $248,012 |
| ASHLEY HUNTER | SENIOR DIRECTOR, MARKETING | 50.00 |
Highest
|
$186,314 | $42,659 | $228,973 |
| WILLIAM OH LEFT 42024 | EVP, CHIEF MEDICAL OFFICER | 50.00 |
Key Emp
|
$185,984 | $26,801 | $212,785 |
| THE REVEREND ROSEY GRIER | DIRECTOR | 10.00 |
Director
|
$42,000 | $0 | $42,000 |
| MICHAEL MILKEN | FOUNDER & CHAIRMAN | 15.00 |
Officer
Director
|
$0 | $0 | $0 |
| LORI MILKEN | DIRECTOR/VP | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| RALPH FINERMAN | CFO, TREASURER, SECRETARY | 10.00 |
Officer
|
$0 | $0 | $0 |
| KELVIN A BAGGET | DIR; SR MANAGING DIR, PATIENT SQUARE CAPITAL | 2.00 |
Director
|
$0 | $0 | $0 |
| EMILIO BASSINI | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| PATRICIA BERNS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| GREGORY BROWN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| STEVEN A BURD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JOSH COHEN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| NEIL P DEFEO | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID A EDERER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| HELMY ELTOUKHY | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JONATHAN P EVANS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| R CHRISTIAN B EVENSEN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| PETER T GRAUER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| STEIN ERIK HAGEN RETIRED 52024 | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| PHILIP KANTOFF MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| FREDA LEWIS-HALL MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| THE HONORABLE EARLE I MACK | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SHMUEL MEITAR | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL MULDOWNEY | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| HENRY L NORDHOFF | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID DREW PINSKY | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| NEAL I RODIN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JASON J SAFRIET | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| RICHARD V SANDLER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JONATHAN W SIMONS MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| KEITH SHOATES | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| HOWARD SHORE | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DAVID TAGLIGHT | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| VINCENT J VIOLA | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| KNEELAND YOUNGBLOOD MD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JEFF ZISK | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $56,686,215 | $58,177,919 | $105,767,424 | $-1,491,704 |
| 2023 | $57,291,095 | $55,134,763 | $91,770,978 | $2,156,332 |
| 2022 | $71,921,851 | $61,472,068 | $87,285,836 | $10,449,783 |
| 2021 | $53,016,750 | $41,671,787 | $62,542,873 | $11,344,963 |
| 2020 | $36,156,917 | $34,952,661 | $43,129,058 | $1,204,256 |
Compare PROSTATE CANCER FOUNDATION with other nonprofits in California and across the country.